SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

Search

Fagron

Uždarymo kaina

SektoriusSveikatos priežiūra

24.25 2.32

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

24.25

Max

24.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-99K

45M

Pardavimai

-98K

476M

P/E

Sektoriaus vid.

18.508

63.808

Dividendų pajamingumas

1.75

Pelno marža

9.55

Darbuotojai

4,193

EBITDA

11M

98M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.75%

2.38%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

54M

1.7B

Ankstesnė atidarymo kaina

21.93

Ankstesnė uždarymo kaina

24.25

Naujienos nuotaikos

By Acuity

50%

50%

150 / 348 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-17 20:26; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

2026-04-17 18:15; UTC

Svarbiausios naujienos

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

2026-04-17 16:49; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026-04-18 01:00; UTC

Svarbiausios naujienos

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

2026-04-17 22:58; UTC

Uždarbis

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026-04-17 21:32; UTC

Rinkos pokalbiai

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Moody's Downgrades Belgium to A1 -- Market Talk

2026-04-17 20:52; UTC

Uždarbis

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026-04-17 20:50; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-04-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-17 20:29; UTC

Uždarbis

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

2026-04-17 20:11; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Buy Neurona Therapeutics for Up to $1.15B

2026-04-17 19:34; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-04-17 19:34; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

2026-04-17 19:31; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

2026-04-17 19:26; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Edge Up -- Market Talk

2026-04-17 19:21; UTC

Rinkos pokalbiai

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

2026-04-17 19:15; UTC

Rinkos pokalbiai

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

2026-04-17 19:07; UTC

Rinkos pokalbiai

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

2026-04-17 18:57; UTC

Svarbiausios naujienos

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

2026-04-17 18:53; UTC

Įsigijimai, susijungimai, perėmimai

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

2026-04-17 18:53; UTC

Įsigijimai, susijungimai, perėmimai

UCB 2026 Rev Guidance Unchanged

2026-04-17 18:52; UTC

Įsigijimai, susijungimai, perėmimai

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

2026-04-17 18:52; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

2026-04-17 18:14; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

2026-04-17 18:00; UTC

Svarbiausios naujienos

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

2026-04-17 18:00; UTC

Svarbiausios naujienos

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

2026-04-17 17:31; UTC

Rinkos pokalbiai
Svarbiausios naujienos

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

2026-04-17 17:26; UTC

Rinkos pokalbiai
Uždarbis

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

150 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat